Cyclosporine-a attenuates retinal inflammation by inhibiting HMGB-1 formation in rats with type 2 diabetes mellitus
BACKGROUND: Cyclosporine-A has been regarded as an immunoregulatory and anti-inflammatory drug for the treatment of various immune inflammatory diseases. However, the effect of Cyclosporine-A on the retina of type 2 diabetic rats and the underlying mechanism remains to be elucidated. The objective of the present study was to investigate the effect and mechanism of Cyclosporine-A on diabetic retinopathy.
METHODS: Male Sprague-Dawley rats were established to type 2 diabetic model. After 6 weeks, diabetic rats and normal controls were intravitreally injected with. Cs-A (42 ng/2 μL) to the left eye, and 2 μL DMSO to the right eye for the control.. Another group of normal wild-type rats was subjected to intravitreal injections into. The left eyes with 5 μL PBS or HMGB-1 (5 ng/5 μL) or HMGB-1(5 ng/5 μL) plus. Cs-A (42 ng/2 μL), respectively. Retinal morphological changes were observed with. Hematoxylin-eosin staining. Expressions of HMGB-1, IL-1β and TNF-α were. Detected by immunohistochemistry, ELISA or Western blot or RT-PCR.
RESULTS: Retinal expression levels of IL-1β and TNF-α were upregulated in type 2. diabetic rats and in normal rats with intravitreal injection of HMGB-1, which were. Attenuated by intravitreal Cs-A. Moreover, Cs-A decreased HMGB-1 expression in. diabetic retina and relieved the retinopathy in type 2 diabetic rats.
CONCLUSIONS: Intravitreal administration of Cs-A showed a protective effect on retina. of diabetic rats, possibly by downregulating retinal expressions of IL-1β and TNF-α. via the suppression of HMGB-1.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
BMC pharmacology & toxicology - 21(2020), 1 vom: 04. Feb., Seite 9 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Peng [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 04.11.2020 Date Revised 04.11.2020 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s40360-020-0387-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM306144158 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM306144158 | ||
003 | DE-627 | ||
005 | 20231225122721.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s40360-020-0387-6 |2 doi | |
028 | 5 | 2 | |a pubmed24n1020.xml |
035 | |a (DE-627)NLM306144158 | ||
035 | |a (NLM)32019593 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Peng |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cyclosporine-a attenuates retinal inflammation by inhibiting HMGB-1 formation in rats with type 2 diabetes mellitus |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.11.2020 | ||
500 | |a Date Revised 04.11.2020 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Cyclosporine-A has been regarded as an immunoregulatory and anti-inflammatory drug for the treatment of various immune inflammatory diseases. However, the effect of Cyclosporine-A on the retina of type 2 diabetic rats and the underlying mechanism remains to be elucidated. The objective of the present study was to investigate the effect and mechanism of Cyclosporine-A on diabetic retinopathy | ||
520 | |a METHODS: Male Sprague-Dawley rats were established to type 2 diabetic model. After 6 weeks, diabetic rats and normal controls were intravitreally injected with. Cs-A (42 ng/2 μL) to the left eye, and 2 μL DMSO to the right eye for the control.. Another group of normal wild-type rats was subjected to intravitreal injections into. The left eyes with 5 μL PBS or HMGB-1 (5 ng/5 μL) or HMGB-1(5 ng/5 μL) plus. Cs-A (42 ng/2 μL), respectively. Retinal morphological changes were observed with. Hematoxylin-eosin staining. Expressions of HMGB-1, IL-1β and TNF-α were. Detected by immunohistochemistry, ELISA or Western blot or RT-PCR | ||
520 | |a RESULTS: Retinal expression levels of IL-1β and TNF-α were upregulated in type 2. diabetic rats and in normal rats with intravitreal injection of HMGB-1, which were. Attenuated by intravitreal Cs-A. Moreover, Cs-A decreased HMGB-1 expression in. diabetic retina and relieved the retinopathy in type 2 diabetic rats | ||
520 | |a CONCLUSIONS: Intravitreal administration of Cs-A showed a protective effect on retina. of diabetic rats, possibly by downregulating retinal expressions of IL-1β and TNF-α. via the suppression of HMGB-1 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Cyclosporine-a | |
650 | 4 | |a Diabetic retinopathy | |
650 | 4 | |a HMGB-1 | |
650 | 4 | |a IL-1β | |
650 | 4 | |a Inflammation | |
650 | 4 | |a TNF-α | |
650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
650 | 7 | |a HMGB1 Protein |2 NLM | |
650 | 7 | |a Hbp1 protein, rat |2 NLM | |
650 | 7 | |a IL1B protein, rat |2 NLM | |
650 | 7 | |a Interleukin-1beta |2 NLM | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
650 | 7 | |a Cyclosporine |2 NLM | |
650 | 7 | |a 83HN0GTJ6D |2 NLM | |
700 | 1 | |a Chen, Fei |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Xuedong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC pharmacology & toxicology |d 2012 |g 21(2020), 1 vom: 04. Feb., Seite 9 |w (DE-627)NLM220735107 |x 2050-6511 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2020 |g number:1 |g day:04 |g month:02 |g pages:9 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40360-020-0387-6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2020 |e 1 |b 04 |c 02 |h 9 |